Synergy Asset Management LLC Purchases 152,788 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Synergy Asset Management LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 391.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 191,805 shares of the biopharmaceutical company’s stock after purchasing an additional 152,788 shares during the period. Gilead Sciences makes up about 1.3% of Synergy Asset Management LLC’s holdings, making the stock its 17th biggest position. Synergy Asset Management LLC’s holdings in Gilead Sciences were worth $17,309,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the third quarter worth about $25,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the second quarter valued at approximately $33,000. Finally, Friedenthal Financial bought a new position in shares of Gilead Sciences during the 3rd quarter valued at $50,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $95.59 on Thursday. The stock has a 50 day moving average of $92.00 and a 200 day moving average of $85.44. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market cap of $119.13 billion, a PE ratio of 1,062.11, a PEG ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. On average, research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last quarter. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on GILD shares. Piper Sandler lifted their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Truist Financial upped their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.